Amid ongoing controversy over a federal drug discount program for safety-net hospitals, a new survey finds a dozen state Medicaid programs rely on an arguably inadequate method to avoid receiving duplicate rebates, which could provide a boost for taxpayers but hurt the pharmaceutical industry’s bottom line.
At issue is the interplay between Medicaid and the so-called 340B program, which was created in 1992 and requires drug makers to offer discounts of up to 50% on all outpatient drugs — for everything from AIDS to diabetes — to hospitals and clinics that serve indigent populations. There are approximately 12,400 so-called covered entities participating in the program, according to the U.S. Human Resources and Services Administration.
Continue to STAT Plus to read the full story…
Anupam Ghose, a physician by training, was diagnosed with Type 2 Diabetes Mellitus (T2DM) in 2017. After the diagnosis of T2DM, he followed a low carbohydrate high fat diet and reversed his T2DM within a year. Now he has one main goal in life and that is to make people understand that the conventional method of treating T2DM is not beneficial. Type 2 diabetes is reversible and the best way to reverse T2DM is through diet and lifestyle modifications. He now decided to help people with type 2 diabetes by offering online coaching to reverse their diabetes.